$7.23
3.60% day before yesterday
Nasdaq, May 30, 10:00 pm CET
ISIN
US03476J1079
Symbol
ELTX
Sector
Industry

Angion Biomedica Corp Stock price

$7.23
+2.31 46.95% 1M
+2.03 39.04% 6M
+2.13 41.76% YTD
-0.28 3.73% 1Y
-7.77 51.80% 3Y
-162.97 95.75% 5Y
-162.97 95.75% 10Y
Nasdaq, Closing price Fri, May 30 2025
-0.27 3.60%
ISIN
US03476J1079
Symbol
ELTX
Sector
Industry

Key metrics

Market capitalization $115.66m
Enterprise Value $97.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 12.97
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-45.48m
Free Cash Flow (TTM) Free Cash Flow $-35.07m
Cash position $18.35m
EPS (TTM) EPS $-3.95
P/E forward negative
Short interest 1.65%
Show more

Is Angion Biomedica Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Angion Biomedica Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Angion Biomedica Corp forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Angion Biomedica Corp forecast:

Buy
67%
Hold
33%

Financial data from Angion Biomedica Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
5% 5%
-
- Research and Development Expense 34 34
31% 31%
-
-44 -44
19% 19%
-
- Depreciation and Amortization 1.37 1.37
211% 211%
-
EBIT (Operating Income) EBIT -45 -45
21% 21%
-
Net Profit -51 -51
31% 31%
-

In millions USD.

Don't miss a Thing! We will send you all news about Angion Biomedica Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Angion Biomedica Corp Stock News

Neutral
GlobeNewsWire
19 days ago
Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025
Neutral
GlobeNewsWire
about 2 months ago
BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on April 15, 2025, Elicio granted inducement awards to Elicio's newly appointed Chief Strategy and Financial Officer, Preetam Shah, and two a...
Neutral
GlobeNewsWire
2 months ago
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025
More Angion Biomedica Corp News

Company Profile

Angion Biomedica Corp. operates as a biopharmaceutical company. It focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 06, 1998 and is headquartered in Uniondale, NY.

Head office United States
CEO Robert Connelly
Employees 32
Founded 2011
Website elicio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today